Ascentage Pharma Group International (6855.HK)
HKD 44.1
(6.78%)
HKD 44.1
(6.78%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -726.07 Million | -653.91 Million | -604.67 Million | -609.95 Million | -460.3 Million | -237.66 Million |
| Net Income | -932.86 Million | -882.92 Million | -782.42 Million | -677.6 Million | -1.48 Billion | -346.9 Million |
| Depreciation & Amortization | 93.19 Million | 60.91 Million | 27.52 Million | 26.48 Million | 25.79 Million | 18.46 Million |
| Deferred income taxes | -4.82 Million | -16.19 Million | 10.92 Million | -26.29 Million | -81.96 Million | -11.39 Million |
| Stock-based compensation | 31.5 Million | 22.1 Million | 46.97 Million | 74.02 Million | 70.82 Million | 27.57 Million |
| Change in working capital | -9.14 Million | -5.9 Million | -57.89 Million | -47.73 Million | 11.14 Million | 27.07 Million |
| Other non-cash items | 96.05 Million | 168.09 Million | 150.21 Million | 41.16 Million | 994.61 Million | 47.52 Million |
| Investing Cash Flow | 21.92 Million | -384.61 Million | -466.52 Million | -107.36 Million | -201.33 Million | 292.8 Million |
| Investments in PPE | -56.84 Million | -203.28 Million | -435.41 Million | -249.92 Million | -77.45 Million | -49.46 Million |
| Acquisitions | -20 Million | -20 Million | -36.2 Million | -144.1 Million | -19.6 Million | -33.37 Million |
| Investment purchases | - | -130 Million | -1.78 Billion | -2.17 Billion | -1.8 Billion | - |
| Sales/Maturities of investments | - | 150 Million | 1.78 Billion | 2.31 Billion | 1.82 Billion | - |
| Other Investing Activities | 98.76 Million | -181.32 Million | -879 Thousand | 142.55 Million | -123.87 Million | 375.64 Million |
| Financing Cash Flow | 368.75 Million | 619.26 Million | 1.78 Billion | 1.04 Billion | 442.36 Million | 860.16 Million |
| Debt repayment | -956.09 Million | -67.74 Million | -60.24 Million | -102.67 Million | -42.66 Million | -50 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -5.92 Million | -26.77 Million | -25.87 Million | - | - | -75.59 Million |
| Common Stock Issuance | 470.08 Million | 19 Thousand | 1.3 Billion | 634.21 Million | 432.27 Million | 15 Thousand |
| Other Financing Activities | 10.29 Million | 808.26 Million | 1.78 Billion | 508.45 Million | 52.74 Million | 1.06 Billion |
| Accounts receivables | -91.53 Million | -388 Thousand | -53.96 Million | - | - | - |
| Accounts payables | 91.53 Million | -110.27 Million | 17.01 Million | - | - | - |
| Inventory | -6.71 Million | -5.51 Million | -3.93 Million | - | - | - |
| Other working capital | -2.42 Million | 110.27 Million | -17.01 Million | -47.73 Million | 11.14 Million | 14.74 Million |
| Cash at beginning of period | 1.34 Billion | 1.7 Billion | 1.01 Billion | 738.98 Million | 957.08 Million | 14.82 Million |
| Cash at end of period | 1.03 Billion | 1.34 Billion | 1.7 Billion | 1.01 Billion | 738.98 Million | 957.08 Million |
| Capital Expenditure | -56.84 Million | -203.28 Million | -435.41 Million | -249.92 Million | -77.45 Million | -49.46 Million |
| Effect of forex changes on cash | 27.81 Million | 58.01 Million | -23.27 Million | -41.68 Million | 1.17 Million | 26.96 Million |
| Net cash flow / Change in cash | -307.59 Million | -361.24 Million | 686.9 Million | 280.99 Million | -218.1 Million | 942.26 Million |
| Free Cash Flow | -782.92 Million | -857.2 Million | -1.04 Billion | -859.87 Million | -537.76 Million | -287.12 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 163 Million | -523.28 Million | -932.86 Million | -402.35 Million | -882.92 Million | -476.19 Million |
| Depreciation & Amortization | 47.31 Million | 47.61 Million | 93.19 Million | 45.57 Million | 60.91 Million | 29.87 Million |
| Deferred income taxes | - | - | -4.82 Million | - | -16.19 Million | -10.62 Million |
| Stock-based compensation | 8.73 Million | 13.25 Million | 31.5 Million | 18.24 Million | 22.1 Million | 16.52 Million |
| Change in working capital | - | -69.01 Million | -9.14 Million | - | -5.9 Million | 104.37 Million |
| Other non-cash items | -573.43 Million | 173.81 Million | 96.05 Million | -29.93 Million | 168.09 Million | 6.7 Million |
| Investing Cash Flow | -131.27 Million | 86.69 Million | 21.92 Million | -64.77 Million | -384.61 Million | -242.01 Million |
| Investments in PPE | -16.52 Million | -12.13 Million | -56.84 Million | -33.97 Million | -203.28 Million | -91.84 Million |
| Acquisitions | - | -20 Million | -20 Million | - | -20 Million | -20 Million |
| Investment purchases | - | - | - | - | -130 Million | - |
| Sales/Maturities of investments | - | - | - | - | 150 Million | - |
| Other Investing Activities | -114.75 Million | 118.82 Million | 98.76 Million | -30.79 Million | -181.32 Million | -130.16 Million |
| Financing Cash Flow | 396.9 Million | -86.88 Million | 368.75 Million | 455.63 Million | 619.26 Million | 171.51 Million |
| Debt repayment | -98.85 Million | - | -956.09 Million | -120.36 Million | -67.74 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.95 Million | -12.3 Million | -5.92 Million | - | -26.77 Million | -26.77 Million |
| Common Stock Issuance | - | - | 470.08 Million | - | 19 Thousand | - |
| Other Financing Activities | 497.71 Million | -74.57 Million | 10.29 Million | 575.99 Million | 808.26 Million | 198.28 Million |
| Accounts receivables | - | -91.53 Million | -91.53 Million | - | -388 Thousand | -388 Thousand |
| Accounts payables | - | - | 91.53 Million | - | -110.27 Million | - |
| Inventory | - | -6.71 Million | -6.71 Million | - | -5.51 Million | -5.51 Million |
| Other working capital | - | 29.24 Million | -2.42 Million | - | 110.27 Million | 110.27 Million |
| Cash at beginning of period | 1.03 Billion | 1.38 Billion | 1.34 Billion | 1.34 Billion | 1.7 Billion | 1.69 Billion |
| Cash at end of period | 952.43 Million | 1.03 Billion | 1.03 Billion | 1.38 Billion | 1.34 Billion | 1.34 Billion |
| Capital Expenditure | -16.52 Million | -12.13 Million | -56.84 Million | -33.97 Million | -203.28 Million | -91.84 Million |
| Effect of forex changes on cash | 3.14 Million | 5.85 Million | 27.81 Million | 21.95 Million | 58.01 Million | 44.18 Million |
| Net cash flow / Change in cash | -85.61 Million | -351.94 Million | -307.59 Million | 44.35 Million | -361.24 Million | -345.03 Million |
| Free Cash Flow | -370.91 Million | -369.74 Million | -782.92 Million | -402.43 Million | -857.2 Million | -410.55 Million |
GW1
MSFT
1219
089980
HINDALCO
3924